NextCure presents initial data from trial of NC762, progress for NC410 combo

NextCure announced that clinical trial investigator Emese Zsiros, M.D., Ph.D. will present initial clinical data from a Phase 1 clinical trial of NC762 and Eric Christenson, M.D. will present a Trials in Progress poster for a combo study of NC410 at the Society for Immunotherapy of Cancer, SITC, annual meeting in Boston. The initial clinical data come from a Phase 1 study evaluating NC762, a monoclonal antibody that binds specifically to B7-H4, in patients with advanced/metastatic solid tumors. "We are pleased to share initial clinical data from our ongoing NC762 Phase 1 trial and provide additional details on our newly announced NC410 combination trial," said Han Myint, M.D., NextCure’s chief medical officer. "We look forward to continuing NC762 in expansion cohorts where we will prospectively select B7-H4-positive tumors as assessed by a CLIA-validated assay we designed. In addition, we are excited to enroll the safety component of the NC410 combo trial and to report initial data in mid-2023."